JNJ). The Company announced on June 16, 2017, that it has completed the acquisition of Actelion Ltd for an about $30 billion in cash. The acquisition was completed under an all-cash public tender offer by Johnson & Johnson's Swiss subsidiary, Janssen Holding GmbH. Post the transaction, Actelion will become part of the Janssen Pharmaceutical Companies of Johnson & Johnson. For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on JNJ. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=JNJ

Details of the Announcement

Founded in the year 1997, and based in Basel, Actelion Pharmaceuticals is a leading firm in the field of pulmonary arterial hypertension (PAH). The Company's portfolio of PAH treatments includes the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. This agreement is set to create a stronger pharmaceutical business for Johnson & Johnson, with leading and differentiated in-market medicines and promising late stage products.

Actelion's PAH franchise includes differentiated, innovative medicines, including, Opsumit®, Uptravi®, and Tracleer®1, which further expands the Janssen Business and provides the Company a leading commercial position in the segment of medical innovation with serious illness and significant unmet medical needs.

This transaction comes on the heels of the agreement announced on January 26, 2017, pursuant to which Johnson & Johnson agreed to acquire Actelion for $30 billion, with a spin-out of a new R&D Company. Actelion spun out its drug discovery operations and early-stage clinical development assets into a newly designated Swiss biopharmaceutical Company, Idorsia, Ltd. A Johnson & Johnson subsidiary will initially hold 9.9% of the shares of Idorsia, Ltd, and it will have the rights to potentially increase up to 32% on a convertible note.

Idorsia

Idorsia, headed by Jean-Paul Clozel (founder of Actelion), is not expected to generate significant revenues for the next 3 years. Under the terms of the agreement, Actelion's shareholders are entitled to receive $280 in cash and a share in Idorsia for each of their shares. Idorsia was launched with SFR 1.00 billion in cash and multiple under-development drugs under its portfolio. The Company's pipeline of drugs in development included treatments for central nervous system, cardiovascular, and immunological disorders.

This agreement covers dual endothelin receptor antagonist ACT-132577, one of four phase-2 assets in Idorsia's pipeline. Actelion recently posted data from a phase-trial of ACT-132577 in May 2017. Johnson & Johnson has the option to pay $230 million and commit to royalties that range from 20% to 35% to opt-in. ACT-132577 is one of the primary Idorsia assets, moving towards phase-3 of developments.

Johnson & Johnson expects the transaction to be accretive to its net sales and views about $1.3 billion in sales for 2017, through this agreement. The Company expects the transaction to be accretive to 2017 adjusted EPS by about $0.07. In the first full-year post the closure of the transaction, Johnson & Johnson expects the transaction to be accretive to its adjusted earnings per share by $0.35 to $0.40.

Last Close Stock Review

At the closing bell, on Friday, June 16, 2017, Johnson & Johnson's stock marginally rose 0.98%, ending the trading session at $134.35. A total volume of 12.26 million shares have exchanged hands, which was higher than the 3-month average volume of 5.81 million shares. The Company's stock price surged 4.91% in the last three months, 16.84% in the past six months, and 15.18% in the previous twelve months. Moreover, the stock rallied 16.61% since the start of the year. The stock is trading at a PE ratio of 22.58 and has a dividend yield of 2.50%. The stock currently has a market cap of $363.63 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 466128

"/> Featured Company News – J&J Completes Actelion Acquisition « MarketersMedia – Press Release Distribution Services – News Release Distribution Services

Featured Company News – J&J Completes Actelion Acquisition

LONDON, UK / ACCESSWIRE / June 19, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Johnson & Johnson (NYSE: JNJ). The Company announced on June 16, 2017, that it has completed the acquisition of Actelion Ltd for an about $30 billion in cash. The acquisition was completed under an all-cash public tender offer by Johnson & Johnson's Swiss subsidiary, Janssen Holding GmbH. Post the transaction, Actelion will become part of the Janssen Pharmaceutical Companies of Johnson & Johnson. For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on JNJ. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=JNJ

Details of the Announcement

Founded in the year 1997, and based in Basel, Actelion Pharmaceuticals is a leading firm in the field of pulmonary arterial hypertension (PAH). The Company's portfolio of PAH treatments includes the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. This agreement is set to create a stronger pharmaceutical business for Johnson & Johnson, with leading and differentiated in-market medicines and promising late stage products.

Actelion's PAH franchise includes differentiated, innovative medicines, including, Opsumit®, Uptravi®, and Tracleer®1, which further expands the Janssen Business and provides the Company a leading commercial position in the segment of medical innovation with serious illness and significant unmet medical needs.

This transaction comes on the heels of the agreement announced on January 26, 2017, pursuant to which Johnson & Johnson agreed to acquire Actelion for $30 billion, with a spin-out of a new R&D Company. Actelion spun out its drug discovery operations and early-stage clinical development assets into a newly designated Swiss biopharmaceutical Company, Idorsia, Ltd. A Johnson & Johnson subsidiary will initially hold 9.9% of the shares of Idorsia, Ltd, and it will have the rights to potentially increase up to 32% on a convertible note.

Idorsia

Idorsia, headed by Jean-Paul Clozel (founder of Actelion), is not expected to generate significant revenues for the next 3 years. Under the terms of the agreement, Actelion's shareholders are entitled to receive $280 in cash and a share in Idorsia for each of their shares. Idorsia was launched with SFR 1.00 billion in cash and multiple under-development drugs under its portfolio. The Company's pipeline of drugs in development included treatments for central nervous system, cardiovascular, and immunological disorders.

This agreement covers dual endothelin receptor antagonist ACT-132577, one of four phase-2 assets in Idorsia's pipeline. Actelion recently posted data from a phase-trial of ACT-132577 in May 2017. Johnson & Johnson has the option to pay $230 million and commit to royalties that range from 20% to 35% to opt-in. ACT-132577 is one of the primary Idorsia assets, moving towards phase-3 of developments.

Johnson & Johnson expects the transaction to be accretive to its net sales and views about $1.3 billion in sales for 2017, through this agreement. The Company expects the transaction to be accretive to 2017 adjusted EPS by about $0.07. In the first full-year post the closure of the transaction, Johnson & Johnson expects the transaction to be accretive to its adjusted earnings per share by $0.35 to $0.40.

Last Close Stock Review

At the closing bell, on Friday, June 16, 2017, Johnson & Johnson's stock marginally rose 0.98%, ending the trading session at $134.35. A total volume of 12.26 million shares have exchanged hands, which was higher than the 3-month average volume of 5.81 million shares. The Company's stock price surged 4.91% in the last three months, 16.84% in the past six months, and 15.18% in the previous twelve months. Moreover, the stock rallied 16.61% since the start of the year. The stock is trading at a PE ratio of 22.58 and has a dividend yield of 2.50%. The stock currently has a market cap of $363.63 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 466128

LONDON, UK / ACCESSWIRE / June 19, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Johnson & Johnson (NYSE: JNJ). The Company announced on June 16, 2017, that it has completed the acquisition of Actelion Ltd for an about $30 billion in cash. The acquisition was completed under an all-cash public tender offer by Johnson & Johnson's Swiss subsidiary, Janssen Holding GmbH. Post the transaction, Actelion will become part of the Janssen Pharmaceutical Companies of Johnson & Johnson. For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on JNJ. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=JNJ

Details of the Announcement

Founded in the year 1997, and based in Basel, Actelion Pharmaceuticals is a leading firm in the field of pulmonary arterial hypertension (PAH). The Company's portfolio of PAH treatments includes the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. This agreement is set to create a stronger pharmaceutical business for Johnson & Johnson, with leading and differentiated in-market medicines and promising late stage products.

Actelion's PAH franchise includes differentiated, innovative medicines, including, Opsumit®, Uptravi®, and Tracleer®1, which further expands the Janssen Business and provides the Company a leading commercial position in the segment of medical innovation with serious illness and significant unmet medical needs.

This transaction comes on the heels of the agreement announced on January 26, 2017, pursuant to which Johnson & Johnson agreed to acquire Actelion for $30 billion, with a spin-out of a new R&D Company. Actelion spun out its drug discovery operations and early-stage clinical development assets into a newly designated Swiss biopharmaceutical Company, Idorsia, Ltd. A Johnson & Johnson subsidiary will initially hold 9.9% of the shares of Idorsia, Ltd, and it will have the rights to potentially increase up to 32% on a convertible note.

Idorsia

Idorsia, headed by Jean-Paul Clozel (founder of Actelion), is not expected to generate significant revenues for the next 3 years. Under the terms of the agreement, Actelion's shareholders are entitled to receive $280 in cash and a share in Idorsia for each of their shares. Idorsia was launched with SFR 1.00 billion in cash and multiple under-development drugs under its portfolio. The Company's pipeline of drugs in development included treatments for central nervous system, cardiovascular, and immunological disorders.

This agreement covers dual endothelin receptor antagonist ACT-132577, one of four phase-2 assets in Idorsia's pipeline. Actelion recently posted data from a phase-trial of ACT-132577 in May 2017. Johnson & Johnson has the option to pay $230 million and commit to royalties that range from 20% to 35% to opt-in. ACT-132577 is one of the primary Idorsia assets, moving towards phase-3 of developments.

Johnson & Johnson expects the transaction to be accretive to its net sales and views about $1.3 billion in sales for 2017, through this agreement. The Company expects the transaction to be accretive to 2017 adjusted EPS by about $0.07. In the first full-year post the closure of the transaction, Johnson & Johnson expects the transaction to be accretive to its adjusted earnings per share by $0.35 to $0.40.

Last Close Stock Review

At the closing bell, on Friday, June 16, 2017, Johnson & Johnson's stock marginally rose 0.98%, ending the trading session at $134.35. A total volume of 12.26 million shares have exchanged hands, which was higher than the 3-month average volume of 5.81 million shares. The Company's stock price surged 4.91% in the last three months, 16.84% in the past six months, and 15.18% in the previous twelve months. Moreover, the stock rallied 16.61% since the start of the year. The stock is trading at a PE ratio of 22.58 and has a dividend yield of 2.50%. The stock currently has a market cap of $363.63 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 466128

Source URL: https://marketersmedia.com/featured-company-news-jj-completes-actelion-acquisition/209269

Source: AccessWire

Release ID: 209269


Latest News